An Audience With in 2013

Filter By:

Article Type
Year

  • With European regulators preparing to launch an adaptive licensing pilot programme, Gigi Hirsch, from MIT, discusses the promise of a more flexible approach to drug approval.

    An Audience With

  • Charles Hugh-Jones, Chief Medical Officer in North America at Sanofi, discusses Project Data Sphere, a new collaborative platform for sharing cancer clinical trial data.

    An Audience With

  • The NIH's Dan Tagle discusses the promise of exRNA, the focus of a US$17 million funding programme.

    An Audience With

  • Daniel Hayes discusses how to break the vicious cycle that is keeping biomarkers down.

    An Audience With

  • Tachi Yamada, Takeda's Chief Medical & Scientific Officer, discusses changes at Takeda and in the Japanese pharmaceutical industry.

    An Audience With

  • The lead author of the ASCO's draft guidelines to “raise the bar” for cancer clinical trials discusses the aims and potential impact of the guidelines on anticancer drug development.

    An Audience With

  • The new Chairman of NICE discusses value-based pricing, cost–benefit appraisals of drugs for rare diseases and the organization's expanded remit.

    • Mullard Asher
    An Audience With

  • Menelas Pangalos, Executive Vice President of Innovative Medicines at AstraZeneca, discusses the company's R&D strategy.

    • Asher Mullard
    An Audience With

  • Henry Chesbrough, a professor at the University of California in Berkeley and popularizer of 'open innovation', discusses the trends and limitations of the business approach.

    • Asher Mullard
    An Audience With

  • Paul Stoffels, Johnson & Johnson's Chief Scientific Officer, discusses the company's approach to partnering.

    An Audience With

  • Chris Austin, Director of the National Center for Advancing Translational Sciences, discusses his plans to tackle the “tragedy of the commons” drug discovery problems.

    An Audience With

  • Mike Yeadon discusses the challenges of starting a company based on assets licensed from Pfizer following the closure of its research operations in Sandwich, UK.

    An Audience With